Shanghai Pharmaceuticals Holding (02607) announced its interim results, with a net profit attributable to shareholders of approximately 4.459 billion yuan, a year-on-year increase of 51.56%.

Shanghai Pharmaceuticals Holding (02607) released its mid-term performance for 2025, with operating income of approximately 141.593 billion yuan, a year-on-year increase of 1.56%; net profit attributable to shareholders of the listed company is around 4.459 billion yuan, a year-on-year increase of 51.56%; basic earnings per share is 1.2 yuan. The announcement stated that the increase in net profit attributable to the parent company was mainly due to a one-time special income resulting from the change in accounting treatment of joint ventures equity accounting for Sinopharm Holdings to subsidiary accounting. After deducting the above-mentioned one-time special gains and losses, the net profit attributable to the parent company was 27.82 billion yuan, a year-on-year decrease of 2.06%.